

FIG. 1

BEST AVAILABLE COPY



FIG. 2c



FIG. 2b



FIG. 2a

FIG. 2f

FIG. 2e

FIG. 2d



FIG. 3c

FIG. 3f

FIG. 3i



FIG. 3b



FIG. 3e

FIG. 3h



FIG. 3a

FIG. 3d



FIG. 3g


SALINE
ANTI-VEGF
IgG
CD3 COUNT (CELLS/GRID)
150
100
50
0
P<0.03
P<0.002
P<0.004
DAY 7
DAY 14
DAY 14

FIG. 3j



FIG. 4c



FIG. 4b



FIG. 4a


IP-10 pg/ml
800
600
400
200
0
0
24
48
72
HRS

FIG. 4e


HRS VEGF 10ng/ml IFN-γ 1000 UNITS/ml
0 2 5 24 48 24
– + + + + –
– + + + + +
IP-10
MCP-1
IL-8
L32
GAPDH
1 2 3 4 5 6 7
Ltn
RANTES
IP-10
MIP-1β
MIP-1α
MCP-1
IL-8
1-309
L32
GAPDH
RELATIVE IP-10/GAPDH EXPRESSION
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1 2 5 24 48 24 HRS
– + + + + – VEGF
– + + + + + IFN-γ

FIG. 4d



FIG. 5c



FIG. 5b



FIG. 5a



FIG. 5h

FIG. 5g

FIG. 5f

FIG. 5e



FIG. 5d

FIG. 5m

FIG. 5l

FIG. 5k

FIG. 5j



FIG. 5i


HUMAN
PROLIFERATION
50000
40000
30000
20000
10000
0
S R 0 .01 .1 .3 1 3 10
ANTI-VEGF (mcg/ml)
MOUSE
PROLIFERATION
50000
40000
30000
20000
10000
0
S R 1:10 1:50 1:100 1:10 1:50 1:100
CONTROL SERUM ANTI-VEGF

FIG. 6a


NUMBER OF SPOTS/WELL
2500
2000
1500
1000
500
0
SYNGENEIC
UNTREATED
ANTI-VEGF

FIG. 6c


INTERFERON-γ
HUMAN
S R 0 .01 .1 .3 1 3 10
ANTI-VEGF (mcg/ml)
INTERLEUKIN-2
HUMAN
S R 0 .01 .1 .3 1 3 10
ANTI-VEGF (mcg/ml)

FIG. 6b


ISOGRAFT
CONTROL Ig
ANTI-VEGF

FIG. 7a


ENDOSTATIN
ENDOSTATIN
UNTREATED

FIG. 7b


ENDOSTATIN (N=8)
UNTREATED (N=10)
GRAFT SURVIVAL (%)
100
80
60
40
20
0
5
10
15
20
25
DAYS AFTER TRANSPLANTATION

FIG. 7d

CD3

FIG. 7c



FIG. 8a



FIG. 8b



FIG. 8c


SYN
Allo
ANTI-VEGF
ICAM-1
E-SELECTIN
VCAM-I
L32
GAPDH
RELATIVE EXPRESSION (adh mol/GAPDH)
0.0
0.2
0.4
0.6
0.8

FIG. 9a


SYN
Allo
ANTI-VEGF
- - - + +
Ltn
Rantes
Eotaxin
Mip-1β
MIP-1α
Mip-2
IP-10
MCF-1
TCA3
L32
GAPDH
TCA-3
MCP-1
IP-10
Mip-2
Mip1a
Mip-1b
RANTES
Ltn
0.0
0.2
0.4
0.6
0.8
RELATIVE EXPRESSION (CHEM/GAPDH)

FIG. 9b


B6 -> BALB
B6 -> BALB/CsA
B6 -> BALB/ANTI-VEGF
B6 -> BALB/CsA + ANTI-VEGF
0
10
20
30
40
DAYS OF SURVIVAL (MEAN ± SEM)

FIG. 10A


● CsA (n=8)
▲ ANTI-VEGF (n=6)
■ ANTI-VEGF + CsA (n=6)
GRAFT SURVIVAL (%)
100
50
0
0
10
20
30
DAYS AFTER TRANSPLANTATION

FIG. 10B



FIG. 11A

FIG. 11B



FIG. 12A



FIG. 12B



FIG. 12C



FIG. 12D



FIG. 13B

SERUM ALANINE AMINOTRANSFERASE (ALT)
90 MIN OF HEPATIC WARM ISCHEMIA FOLLOWED
BY 6 h OF REPERFUSION

SERUM ALT (U/L)	
CONTROL Ab	ANTI-VEGF Ab
6008	423
4464	200
2564	290
1706	934
3352	567
	63
MEAN 3618.8	412.8
SEM 750.5	126.3

FIG. 13A

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☑ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.